Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | F12 | P00748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31707121 | 0.76 | MAP3K14 (0.41) | GRM1CCNA2CDK2CCNA1MAP3K14 | |
| SCHEMBL31706707 | 0.74 | MAP3K14 (0.40) | GRM1CCNA2CDK2CCNA1MAP3K14 | |
| SCHEMBL38652766 | 0.72 | CCNA2 (0.36) | CCNA2CDK2CCNA1HSP90AA1HSP90AB1 | |
| SCHEMBL31707204 | 0.71 | MAP3K14 (0.38) | GRM1CCNA2CDK2CCNA1MAP3K14 | |
| SCHEMBL38654028 | 0.71 | JAK2 (0.34) | CCNA2CDK2CCNA1HSP90AA1HSP90AB1 | |
| SCHEMBL38653833 | 0.71 | CCNA2 (0.41) | CCNA2CDK2CCNA1 | |
| SCHEMBL31707167 | 0.70 | GRM1 (0.38) | GRM1CCNA2CDK2CCNA1MAP3K14 | |
| SCHEMBL30899436 | 0.68 | CCNA2 (0.44) | CCNA2CDK2CCNA1HSP90AA1HSP90AB1 | |
| SCHEMBL31707003 | 0.68 | CCNA2 (0.49) | GRM1CCNA2CDK2CCNA1MAP3K14 | |
| SCHEMBL31707198 | 0.67 | MAP3K14 (0.37) | GRM1CCNA2CDK2CCNA1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130302-A1 | Antiviral Pyrazolopyridinone Compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC | 2021-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130302-A1 | Antiviral Pyrazolopyridinone Compounds | ZC3HAV1, TYMP, ZC3HAV1L | GRM1 2785/4885ADORA1 1493/4885CCNA2 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.